B+
Bull case
0%
Probability
Target price
$27.00
Analysis reference price unavailable
Analysis 2026-09-28 · RankAlpha Sentiment Codex
PRVA
Privia Health GroupCNasdaq / Health Care Equipment & Services
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
1%
Probability
Target price
$21.00
Analysis reference price unavailable
Analysis 2026-09-28 · RankAlpha Sentiment Codex
B-
Bear case
0%
Probability
Target price
$14.00
Analysis reference price unavailable
Analysis 2026-09-28 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-09-28
Recent news sentiment (30D)
-26.0
Negative
Company
-
Unavailable
Macro
-26.0
Negative
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+56.8
Score
AI commentary
The company-confirmed Q2 growth and raised outlook support a positive operating tone. The September 25 anchor is $19.71, but the packet does not establish the immediate post-release price reaction or whether an initial move held. Confirmed analyst revisions, social coverage, options skew, short interest, and employee sentiment are unavailable; zero-valued sentiment fields represent missing data, not neutral readings. The earnings document labeled as a September investor release is third-party valuation commentary, not a company release.
RankAlpha Sentiment Codex - 2026-09-28
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-12-31eventDelivery against raised 2026 outlookHigh impact
Privia reported Q2 revenue of $632.6 million, up 21.4% year over year, and adjusted EBITDA of $37.4 million, up 29.1%. It raised its full-year outlook, including attributed lives to 1.625–1.650 million, while targeting the high end of its prior $2.35–$2.45 billion revenue range. Year-end delivery is the central thesis test; December 31 is a fiscal-year checkpoint, not an announced earnings date [#SEC-8K-2026-08-06].
2026-12-31eventFree-cash-flow conversion testMedium impact
Management expects approximately 70–80% of 2026 adjusted EBITDA to convert to free cash flow, subject to the timing of MSSP cash settlement. Cash realization below that expectation would weaken the quality-of-earnings case [#SEC-8K-2026-08-06].
2027-06-30catalystPhysician-network and value-based-care scalingHigh impact
Q2 implemented providers rose 10.1% to 5,644, attributed lives rose 19.2% to 1.647 million, and platform contribution rose 20.1%. Sustaining those trends could support earnings growth, but this is a monitoring thesis rather than a dated company milestone [#SEC-8K-2026-08-06].
Recommendation
N/A
No formal recommendation provided.
As of 2026-09-28 • Updated nightlySource: Internal modelMethodology